| scholarly article | Q13442814 |
| P50 | author | Lena E Friberg | Q88235607 |
| P2093 | author name string | Otto Cars | |
| Elisabet I Nielsen | |||
| P2860 | cites work | A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design | Q28476705 |
| Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. | Q33559047 | ||
| Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa | Q33876563 | ||
| Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria | Q33976467 | ||
| Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection | Q33976517 | ||
| Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections | Q33983119 | ||
| Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models | Q34108149 | ||
| Animal model pharmacokinetics and pharmacodynamics: a critical review | Q34615868 | ||
| Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models | Q34615883 | ||
| Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model | Q34737629 | ||
| Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model | Q35128808 | ||
| Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. | Q35134599 | ||
| Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy | Q35140423 | ||
| Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation | Q35582365 | ||
| Pharmacodynamics and dosing of aminoglycosides | Q35623060 | ||
| Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments | Q35635652 | ||
| Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis | Q35810298 | ||
| Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients | Q35814807 | ||
| A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function | Q35827765 | ||
| Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update | Q36072639 | ||
| Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks. | Q36095091 | ||
| Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006. | Q36720907 | ||
| First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. | Q36752618 | ||
| Model-based drug development | Q36830686 | ||
| Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development | Q36949430 | ||
| Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects | Q36956331 | ||
| Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. | Q37114216 | ||
| Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens | Q37568933 | ||
| In vitro pharmacodynamic models to determine the effect of antibacterial drugs | Q37660762 | ||
| Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices | Q37706727 | ||
| Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. | Q37733667 | ||
| Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model | Q39478148 | ||
| Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. | Q39784317 | ||
| Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance | Q39828366 | ||
| Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. | Q39881843 | ||
| Role of mechanistically-based pharmacokinetic/pharmacodynamic models in drug development : a case study of a therapeutic protein | Q40349907 | ||
| Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins | Q40431109 | ||
| The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents | Q40517235 | ||
| Pharmacokinetics and pharmacodynamics of antibiotics in otitis media | Q41148314 | ||
| Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 | ||
| Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo. | Q41879559 | ||
| Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models | Q42169493 | ||
| Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa | Q43215544 | ||
| Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model | Q43617611 | ||
| Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model | Q43804203 | ||
| "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy | Q44157139 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia | Q44611157 | ||
| Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling | Q44662037 | ||
| "Getting the dose right": facts, a blueprint, and encouragements | Q44911801 | ||
| Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections | Q45127594 | ||
| Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae | Q45209303 | ||
| Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. | Q45984535 | ||
| Pharmacokinetics of intravenous erythromycin | Q46349003 | ||
| Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine | Q52437136 | ||
| A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions. | Q52623628 | ||
| Population pharmacokinetics of vancomycin in Japanese pediatric patients. | Q54112702 | ||
| Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections | Q54297609 | ||
| Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. | Q54319060 | ||
| Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore | Q58033538 | ||
| Evidence for a Slow Elimination Phase for Penicillin G | Q68438201 | ||
| Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins | Q69572281 | ||
| Netilmicin and gentamicin multidose kinetics in normal subjects | Q71064703 | ||
| AUIC--the universal parameter within the constraint of a reasonable dosing interval | Q71697436 | ||
| Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin | Q73959840 | ||
| Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains | Q79459866 | ||
| Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance--a controlled study | Q80517469 | ||
| Observational trial of a 48-hour gentamicin dosing regimen derived from Monte Carlo simulations in infants born at less than 28 weeks' gestation | Q81549728 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibiotic | Q12187 |
| pharmacokinetics | Q323936 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 4619-4630 | |
| P577 | publication date | 2011-08-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization | |
| P478 | volume | 55 |
| Q91344581 | A dose response model for quantifying the infection risk of antibiotic-resistant bacteria |
| Q38966188 | A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants |
| Q36684146 | A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro. |
| Q31059319 | A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin |
| Q51118472 | A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing. |
| Q34596526 | A population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults |
| Q39451172 | Activity of cefquinome against extended-spectrum β-lactamase-producing Klebsiella pneumoniae in neutropenic mouse thigh model |
| Q48528055 | Amikacin Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis in Pediatric Cancer Patients |
| Q38316070 | Antimicrobial susceptibility testing for bovine respiratory disease: getting more from diagnostic results |
| Q26753831 | Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction |
| Q36171772 | Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill |
| Q38420688 | Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. |
| Q33905531 | Are children undergoing cardiac surgery receiving antibiotics at subtherapeutic levels? |
| Q40108765 | Biofilm formation and antibiotic susceptibility in dispersed cells versus planktonic cells from clinical, industry and environmental origins. |
| Q47897914 | Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data. |
| Q35864589 | Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model |
| Q47371115 | Concentrations of cefuroxime in brain tissue of neurointensive care patients. |
| Q52595189 | Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model. |
| Q48722683 | Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and Simulation |
| Q89982252 | Dose Optimization of Cefpirome Based on Population Pharmacokinetics and Target Attainment during Extracorporeal Membrane Oxygenation |
| Q36109394 | Editorial Comment to Postoperative infectious complications in patients undergoing holmium laser enucleation of the prostate: Risk factors and microbiological analysis |
| Q38121142 | Emerging drugs on methicillin-resistant Staphylococcus aureus |
| Q54251919 | Exploring the Use of C-Reactive Protein to Estimate the Pharmacodynamics of Vancomycin. |
| Q64912442 | Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin. |
| Q40857961 | Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model |
| Q36413575 | Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens |
| Q92302869 | In vitro Pharmacodynamics and PK/PD in Animals |
| Q34299028 | In vivo activity of cefquinome against Escherichia coli in the thighs of neutropenic mice |
| Q40330083 | In vivo activity of cefquinome against Riemerella anatipestifer using the pericarditis model in the duck |
| Q36198218 | Mathematical model on Alzheimer's disease |
| Q47273930 | Mechanism-based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model. |
| Q59808257 | Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae |
| Q101327707 | Model-informed drug development for antimicrobials: Translational PK and PKPD modelling to predict an efficacious human dose for apramycin |
| Q47273948 | Modeling the emergence of antibiotic resistance in the environment: an analytical solution for the minimum selection concentration. |
| Q63346417 | Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice? |
| Q30911044 | Mutant prevention concentration, pharmacokinetic-pharmacodynamic integration, and modeling of enrofloxacin data established in diseased buffalo calves |
| Q38880229 | Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection |
| Q49894254 | On the analysis of complex biological supply chains: From Process Systems Engineering to Quantitative Systems Pharmacology |
| Q38786623 | Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic/pharmacodynamic analysis |
| Q36083619 | Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. |
| Q39108922 | Pharmacokinetic and pharmacodynamic characterization of ceftiofur crystalline-free acid following subcutaneous administration in domestic goats |
| Q40326667 | Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants |
| Q36383878 | Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida |
| Q39019096 | Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida |
| Q93035816 | Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis |
| Q92740182 | Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature |
| Q38664871 | Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. |
| Q44361727 | Pharmacokinetics and residue depletion of erythromycin in gilthead sea bream Sparus aurata L. after oral administration |
| Q46983972 | Pharmacokinetics and residue depletion of erythromycin in rainbow trout Oncorhynchus mykiss (Walbaum). |
| Q88674308 | Pharmacokinetics of cefuroxime in infants and neonates undergoing cardiac surgery |
| Q49791998 | Pharmacokinetics of penicillin G in preterm and term neonates |
| Q39071799 | Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy. |
| Q49064586 | Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures |
| Q38699731 | Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling. |
| Q47236751 | Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria. |
| Q35169043 | Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy |
| Q48514081 | Quantitative analysis of gentamicin exposure in neonates and infants calls into question its current dosing recommendations. |
| Q41967888 | Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy |
| Q40087805 | Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs. |
| Q92430053 | Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii |
| Q39039505 | Translational PK/PD of anti-infective therapeutics. |
| Q38853629 | Translational Pharmacometric Evaluation of Typical Antibiotic Broad-Spectrum Combination Therapies Against Staphylococcus Aureus Exploiting In Vitro Information |
| Q38246118 | Treatment option for sepsis in children in the era of antibiotic resistance |
| Q36242447 | Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies |
| Q89728720 | Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii |
| Q64904032 | VetCAST Method for Determination of the Pharmacokinetic-Pharmacodynamic Cut-Off Values of a Long-Acting Formulation of Florfenicol to Support Clinical Breakpoints for Florfenicol Antimicrobial Susceptibility Testing in Cattle. |
| Q84230576 | [Musculoskeletal infections in the era of multiresistant pathogens] |
Search more.